Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) belonging to the Medical sector has declined -6.19% and closed its last trading session at $0.68.
The company reported its EPS on 11/03/2016. Currently, the stock has a 1 Year Price Target of $1.25.
Navidea Biopharmaceuticals, Inc on 11/03/2016 reported its EPS as $-0.04 with the analysts projecting the EPS of the stock as $-0.03. The company beat the analyst EPS Estimate with the difference of $-0.01. This shows a surprise factor of -33.3%.
Many analysts have provided their estimated foresights on Navidea Biopharmaceuticals, Inc Earnings, with 1 analysts believing the company would generate an Average Estimate of $-0.02. Whereas they predicted High and Low Earnings Estimate as $-0.02 and $-0.02 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.05.
The Company got Initiated by Burrill Institutional Research on 24-Jan-13 to Mkt Outperform.
Insider Trades for Navidea Biopharmaceuticals, Inc show that the latest trade was made on 16 Oct 2016 where Greene (Mark J), the Director completed a transaction type “Buy” in which 11413 shares were traded at a price of $0.87.
Over the period of 6 months, Insider Purchases show a total of 2 transaction in which 30000 shares were traded. 7 Insider Sales transactions were made totaling 95000 shares traded.
1 analysts projected Price Targets for Navidea Biopharmaceuticals, Inc. The analysts believe that the company stock price could grow as high as $1.25. The Low Price target projection by analysts is $1.25 and the Mean Price Target is $1.25.
Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) has the market capitalization of $105.32 Million. The company rocked its 52-Week High of $1.51 on May 3, 2016 and touched its 52-Week Low of $0.26 on Aug 31, 2016. The stock has Return on Assets (ROA) of -109.8 percent. Return on Equity (ROE) stands at 21.5% and Return on Investment (ROI) of -306.8 percent.
The stock is currently showing YTD performance of -48.86 Percent. The company has Beta Value of 0.1 and ATR value of 0.05. The Weekly and Monthly Volatility stands at 4.56% and 6.45%.
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company’s radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and RIGScan(TM). Navidea Biopharmaceuticals, Inc., formerly Neoprobe Corporation, is headquartered in Dublin, Ohio.